FDA
-
-
-
-
-
-
-
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
-
-
-
-
-
-
-
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
-
-
-
-
-
-
-
Teva Pharma (TEVA) PT Raised to $38 at Truist Securities
-
-
-
-
-
-
-
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
-
-
-
-
-
-
-
Medincell: FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
-
-
-
-
-
-
-
Teva (TEVA) outlines acceleration path into a leading biopharma company
-
-
-
-
-
-
-
Alvotech (ALVO) and Teva (TEVA) Announce Filing Acceptance of U.S. Biologics License Applications for AVT05
-
327,802 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

